.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Julphar
Cerilliant
Chubb
Queensland Health
QuintilesIMS
Chinese Patent Office
Deloitte
Citi
US Department of Justice
Farmers Insurance

Generated: December 16, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,684,969

« Back to Dashboard

Which drugs does patent 8,684,969 protect, and when does it expire?


Patent 8,684,969 protects NORDITROPIN FLEXPRO, LEVEMIR FLEXTOUCH, NOVOLOG FLEXTOUCH, FIASP FLEXTOUCH, RYZODEG 70/30, SAXENDA, TRESIBA, and XULTOPHY 100/3.6, and is included in eight NDAs.

This patent has sixteen patent family members in fourteen countries.

Summary for Patent: 8,684,969

Title:Injection device with torsion spring and rotatable display
Abstract: The present invention relates to an injection device comprising a torsion spring operatively connected to a dose setting member being adapted to set a dose to be ejected from the injection device. A rotatably mounted display member adapted to display the dose to be ejected in accordance with a setting of the dose setting member is also provided. The rotatably mounted display member is adapted to be rotated over an angle corresponding to at least one revolution of the display member. The display member may be implemented as a dose indicator barrel having numerals arranged along a helical path on an outer surface thereof, or alternatively, as a counting device having two or more display wheels having numerals arranged on an outer surface thereof.
Inventor(s): Moller; Claus Schmidt (Fredensborg, DK), Markussen; Tom Hede (Bagsvaerd, DK), Enggaard; Christian Peter (Vejby, DK)
Assignee: Novo Nordisk A/S (Bagsvaerd, DK)
Application Number:13/626,541
Patent Claim Types:
see list of patent claims
Device;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Novo Nordisk IncNORDITROPIN FLEXPROsomatropin recombinantINJECTABLE;INJECTION021148-008Mar 1, 2010BXRXNoNo► Subscribe► SubscribeY► Subscribe
Novo Nordisk IncNORDITROPIN FLEXPROsomatropin recombinantINJECTABLE;INJECTION021148-009Mar 1, 2010BXRXNoNo► Subscribe► SubscribeY► Subscribe
Novo Nordisk IncNORDITROPIN FLEXPROsomatropin recombinantINJECTABLE;INJECTION021148-010Mar 1, 2010RXNoNo► Subscribe► SubscribeY► Subscribe
Novo Nordisk IncNORDITROPIN FLEXPROsomatropin recombinantINJECTABLE;INJECTION021148-011Jan 23, 2015RXNoNo► Subscribe► SubscribeY► Subscribe
Novo Nordisk IncLEVEMIR FLEXTOUCHinsulin detemir recombinantINJECTABLE;SUBCUTANEOUS021536-005Oct 31, 2013RXYesYes► Subscribe► SubscribeY► Subscribe
Novo Nordisk IncNOVOLOG FLEXTOUCHinsulin aspart recombinantINJECTABLE;SUBCUTANEOUS020986-005Oct 31, 2013RXYesYes► Subscribe► SubscribeY► Subscribe
Novo Nordisk IncFIASP FLEXTOUCHinsulin aspart recombinantSOLUTION;SUBCUTANEOUS208751-002Sep 29, 2017RXYesYes► Subscribe► SubscribeY► Subscribe
Novo Nordisk IncRYZODEG 70/30insulin aspart; insulin degludecSOLUTION;SUBCUTANEOUS203313-001Sep 25, 2015RXYesYes► Subscribe► SubscribeY► Subscribe
Novo Nordisk IncSAXENDAliraglutide recombinantSOLUTION;SUBCUTANEOUS206321-001Dec 23, 2014RXYesYes► Subscribe► SubscribeY► Subscribe
Novo Nordisk IncTRESIBAinsulin degludecSOLUTION;SUBCUTANEOUS203314-001Sep 25, 2015RXYesNo► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 8,684,969

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
04077899Oct 21, 2004

Non-Orange Book Patents for Patent: 8,684,969

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,357,120Injection device with torsion spring and rotatable display► Subscribe
9,687,611Injection device with torsion spring and rotatable display► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,684,969

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Russian Federation2007114760► Subscribe
South Korea101278123► Subscribe
South Korea20070084392► Subscribe
Japan5185620► Subscribe
Japan2008517233► Subscribe
Israel182616► Subscribe
Spain2334808► Subscribe
European Patent Office1819382► Subscribe
Denmark1819382► Subscribe
Germany602005017182► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Julphar
US Department of Justice
AstraZeneca
Chinese Patent Office
QuintilesIMS
Johnson and Johnson
Boehringer Ingelheim
Colorcon
Merck
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot